Please create an account
or Log in to subscribe


Subscribe to our RSS feeds Follow us on Twitter Follow us on Facebook Subscribe to our RSS feeds Watch us on Youtube View us on Instagram

New drug may delay Alzheimer’s

New drug may delay Alzheimer’s

Is this research going to transform the way we search for a cure?

New drug may delay Alzheimer’s

Results of a study conducted by pharmaceutical company Eli Lilly are suggesting a new drug can reduce the rate of dementia’s progression be approximately a third.

The new drug, Solanezumab, will act to preserve the brain cells and actively protect them by destroying the “deformed proteins” that build up within the brain over time – causing Alzheimer’s.

The current medication available to those with Alzheimer’s simply helps to keep the brain cells that are diminishing, at a functioning level, therefore supplementing without providing a more concrete protection against further decline.

The deformed proteins, called amyloid, are thought to form a sticky membrane between nerve cells that damage the brain cells and inevitably lead to their death.

Data has shown that when used as a treatment for patients in the earliest stages of Alzheimer’s, it appeared to slow the decline by around 34%.

Dr Eric Siemers, from the Lilly Research Laboratories, in Indiana, told the BBC: “It’s another piece of evidence that solanezumab does have an effect on the underlying disease pathology.

“We think there is a chance that solanezumab will be the first disease-modifying medication to be available.”

The trial results were presented at the Alzheimer’s Association International Conference.

Whilst the data is merely a speck in the research needed to conclusively attest to a ‘breakthrough’ in Alzheimer’s treatment, the trial results are useful for conducting further research along the lines of attacking the cells that aid in the decline – instead of treating those that have already diminished.

Clare Walton, the research manager at the Alzheimer’s Society, told the BBC: “The data hints that the antibodies are having an effect, it is promising and it’s better than no effect, but it’s inconclusive.

“After a decade of no treatments and many drug failures, it’s exciting to get promising news, but it doesn’t really tell us either way, and we need to wait for the phase-three study, and that is in 18 months.”



Share on Facebook Pin on Pinterest Share by Email

Post a Comment

© MiNDFOOD 2021. All Rights Reserved

Web Design Sydney